Developing Assays Across Food Allergens

AllerGenis’ researchers are developing a pipeline of assays across a broad array of food allergens. Founded on the epitope mapping research of Hugh Sampson, MD, of the Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai, our diagnostic technology subdivides allergenic proteins into smaller peptides, called epitopes, and measures the reactivity of a patient’s IgE and/or IgG4 to these epitopes. The test is a high-throughput assay using a bead-based immunoassay platform to analyze IgE/IgG4 reactivity to discrete food allergen epitopes from only a few microliters of patient serum in a clinical lab setting in 2-3 hours.

Tree Nut

The Applications for the Allergenis Platform are Broad

Areas of development include: Standalone diagnostic research tool, complementary diagnostic for monitoring and determining therapeutic response over time.

Medical Value

In its full development, the goal of AllerGenis’ technology program will be the ability to:

  • Diagnose patient food allergy and associated disease severity (including anaphylaxis) without the risks associated with oral food challenge.
  • Distinguish between sensitivity and allergic disease, and who will naturally outgrow.
  • Assess, manage and monitor progress of therapy (ex. desensitization).
  • Determine therapeutic efficacy (ex. tolerance threshold).

The first product to be launched using this proprietary technology platform will be AllerGenis’ peanut allergy assay.